Pds biotech announces clinical strategy update and reports full year 2023 financial results

Unique mechanism of action of the combination of pds01adc and versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
PDSB Ratings Summary
PDSB Quant Ranking